Amphastar Wins FDA Approval for Affordable Osteoporosis Treatment
Amphastar Pharmaceuticals receives FDA approval for generic teriparatide injection, offering an affordable alternative to Eli Lilly's FORTEO for osteoporosis patients.
/ 80 items
#LLY↓
Eli Lilly's Groundbreaking Obesity Drug Shows Record-Breaking Weight Loss Results
Eli Lilly's experimental retatrutide helps patients lose up to 24% body weight in trials, setting new standards for obesity treatment but with notable side effects and dropout rates.
Hims Stock Dips as New SAFE Drugs Act Targets Compounded Weight-Loss Medications
Hims shares fell after lawmakers proposed the SAFE Drugs Act, a bill that would restrict compounded versions of popular GLP-1 weight-loss drugs. Analysts say the bill could significantly impact Hims’ fastest-growing product category.
Structure Therapeutics' Obesity Pill Shows Promising Weight Loss Results, Shares Surge
Structure Therapeutics' (GPCR) experimental obesity pill aleniglipron delivers up to 15.3% weight loss in clinical trials, positioning it as a competitive alternative to Eli Lilly's oral treatment with shares more than doubling on promising Phase 2 results.
Stifel Bullish on Foghorn Therapeutics Stock
Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.
Novo Nordisk Stock Plunges 10% as Ozempic Fails Alzheimer's Trial
Novo Nordisk shares tumbled 10% after Ozempic failed to slow Alzheimer's progression in clinical trials, marking another setback for the struggling Danish drugmaker against rival Eli Lilly.